Cargando…
Improving the therapeutic ratio in head and neck cancer /
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a road...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London, United Kingdom ; Cambridge, MA :
Academic Press, an imprint of Elsevier,
[2020]
|
| Edición: | First edition. |
| Colección: | Cancer sensitizing agents for chemotherapy ;
v. 6. |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Improving the Therapeutic Ratio in Head and Neck Cancer; Copyright; Aims and Scope for Series ""Cancer Sensitizing Agents for Chemotherapy; About the Series Editor; About the Editor; Aims and Scope for ""Improving the Therapeutic Ratio in Head and Neck Cancer; Preface; Contents; Contributors; Chapter 1: Overview of head and neck cancer management; Introduction; Anatomy; Clinical evaluation; Oropharynx; Epidemiology; Pathology; Anatomy and staging; General treatment approach; Initial surgery; Initial radiation-based therapy; Key clinical research themes; Nasopharynx; Epidemiology
- PathologyAnatomy and staging; General treatment approach; Key clinical research themes; Oral cavity; Epidemiology and pathology; Anatomy and staging; General treatment approach; Key clinical research themes; Larynx and hypopharynx; Epidemiology and staging; General treatment approach; Key clinical research themes; Salivary gland tumors; Epidemiology and pathology; Anatomy and staging; General treatment approach and key clinical research themes; Recurrent and metastatic squamous cell carcinoma of the head and neck; Conclusion; References
- Chapter 2: The role of molecularly targeted therapies and immunotherapy in head and neck cancerCurrent therapies for recurrent/metastatic disease; Early work with cytotoxic agents; Emergence of targeted therapy against the epidermal growth factor receptor (EGFR); Cetuximab plus chemotherapy in the first line metastatic setting; Panitumumab as an alternative targeted agent for HNSCC; Practical approach to first line systemic treatment; Dawn of an immunotherapy trend; Pembrolizumab; Nivolumab; Durvalumab; Ongoing trials and future directions; Future directions; Acknowledgments; References
- Chapter 3: Combining radiation and chemotherapy to improve the therapeutic ratioBasic principles of radiobiology; Basic principles of radiation-induced cell death; Basic principles of radiotherapy in head and neck cancer management; Basic principles of toxicities of head and neck cancer management; Widening the therapeutic window; Radiotherapy dose/volume reduction in the absence of a surgical component or induction chemotherapy; Radiotherapy dose/volume reduction following induction chemotherapy; Systemic therapy toxicity studies without radiotherapy or surgical components
- Radiotherapy dose/volume reductions with a surgical componentRadiotherapy protectors; Proton therapy; Conclusion; Acknowledgments; References; Chapter 4: Targeting TP53 to augment therapeutic response in head and neck cancer; Introduction; Current treatment for head and neck squamous cell carcinoma (HNSCC); Mutations in TP53 are common deleterious genetic alterations in HNSCC; Tumor suppressive functions of TP53; TP53 mutations as a prognostic and predictive biomarker for poor outcomes in HNSCC; TP53 gene transfer therapy for HNSCC